Cartesian Therapeutics Ownership
$7.22
0.14%
Nasdaq, Oct 01, 04:00 pm EDT.
Closed.
Cartesian Therapeutics Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
Springer Timothy A
|
8.642m | 28.77% | +1.978k | Apr 14 2026 |
| 2 |
Seven One Eight Three Four Irrevocable Trust
INSIDER
|
4.555m | 15.16% | — | Mar 31 2026 |
| 3 |
Squarepoint Capital LLP
|
2.255m | 7.51% | +16.133k | Jun 30 2026 |
| 4 |
BlackRock Institutional Trust Company, N.A.
|
743.396k | 2.47% | +199.477k | Jun 30 2026 |
| 5 |
Singer (Michael S.)
|
685.080k | 2.28% | +1.978k | Apr 14 2026 |
|
1
Springer Timothy A
|
28.77%
8.642m
|
|
2
Seven One Eight Three Four Irrevocable Trust
INSIDER
|
15.16%
4.555m
|
|
3
Squarepoint Capital LLP
|
7.51%
2.255m
|
|
4
BlackRock Institutional Trust Company, N.A.
|
2.47%
743.396k
|
|
5
Singer (Michael S.)
|
2.28%
685.080k
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 56.19% of Cartesian Therapeutics, with Springer Timothy A the biggest at 28.77%, followed by Seven One Eight Three Four Irrevocable Trust (15.16%) and Squarepoint Capital LLP (7.51%). |
Recent Cartesian Therapeutics Insider Transactions
Powered by
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Oct 02 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Sep 29 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Sep 25 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Sep 20 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Sep 14 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Sep 07 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Oct 02 2026
$182.45
|
|
Sarah Chen
SALES
|
Sep 29 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Sep 25 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Sep 20 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Sep 14 2026
$170.50
|
|
Lisa Park
SALES
|
Sep 07 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
Cartesian Therapeutics Short interest
Powered by
| Short interest shows what share of a stock's freely tradable shares (float) is currently sold short, meaning held by investors betting on falling prices. A high or rising level can be read two ways: it reflects the skepticism of many market participants, but also carries upside potential. Because if the stock rises, short sellers have to buy back, which can push the price up even further. This effect is called a short squeeze. | |
| The short interest in Cartesian Therapeutics has fallen over the past 12 months from around 22.5% to 13.0% of the float. Fewer and fewer market participants are betting on falling prices. That points to easing skepticism, as short sellers increasingly unwind their positions. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
